



Universiteit  
Leiden  
The Netherlands

## **Personalised pharmacotherapy in paediatric epilepsy : the path to rational drug and dose selection**

Dijkman, S.C. van

### **Citation**

Dijkman, S. C. van. (2017, November 29). *Personalised pharmacotherapy in paediatric epilepsy : the path to rational drug and dose selection*. Retrieved from <https://hdl.handle.net/1887/59470>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/59470>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The following handle holds various files of this Leiden University dissertation:

<http://hdl.handle.net/1887/59470>

**Author:** Dijkman, S.C. van

**Title:** Personalised pharmacotherapy in paediatric epilepsy : the path to rational drug and dose selection

**Issue Date:** 2017-11-29

# **PERSONALISED PHARMACOTHERAPY IN PAEDIATRIC EPILEPSY: THE PATH TO RATIONAL DRUG AND DOSE SELECTION**

## **Proefschrift**

ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden  
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker  
volgens besluit van het College voor Promoties  
te verdedigen op woensdag 29 november 2017  
klokke 10:00 uur

door

**Sven Christiaan van Dijkman**

geboren te Amsterdam, Nederland  
in 1984

Promotor	Prof. Dr. M. Danhof	Universiteit Leiden
Co-promotor	Prof. Dr. O.E. Della Pasqua	University College London
Promotiecommissie	Prof. Dr. H. Irth, voorzitter	Universiteit Leiden
	Prof. Dr. J.A. Bouwstra, secretaris	Universiteit Leiden
	Prof. Dr. J.W. Sander	University College London
	Prof. Dr. E. Perucca	Università di Pavia
	Prof. Dr. R.A.A. Mathôt	Universiteit van Amsterdam
	Prof. Dr. C.A.J. Knibbe	Universiteit Leiden
	Prof. Dr. H.J. Guchelaar	Universiteit Leiden

# TABLE OF CONTENTS

<b>Section I</b>	<b>General Introduction</b>	
Chapter 1	Pharmacotherapy in pediatric epilepsy: from trial and error to rational drug and dose selection – a long way to go	9
Chapter 2	Scope and intent of investigations	51
<b>Section II</b>	<b>Knowledge integration</b>	
Chapter 3	Pharmacokinetic and pharmacodynamic models for anti-epileptic drugs in adults, children and neonates	75
<b>Section III</b>	<b>Model-based dosing algorithms</b>	
Chapter 4	Pharmacokinetic interactions and dosing rationale for anti-epileptic drugs in adults and children	127
Chapter 5	Individualised dosing algorithms and therapeutic monitoring for anti-epileptic drugs	155
<b>Section IV</b>	<b>Evidence generation and synthesis in epilepsy trials</b>	
Chapter 6	Impact of age-related factors on the pharmacokinetics of lamotrigine and implications for the dose rationale in epilepsy patients	187
Chapter 7	Exposure-response relationships of lamotrigine in partial onset vs. primary generalised tonic-clonic seizures in adults	217
Chapter 8	Exposure-response relationship and dose rationale for lamotrigine in children aged 1-24 months	237
<b>Section V</b>	<b>Conclusions and perspectives</b>	
Chapter 9	Conclusions and Future Perspectives	257
Chapter 10	Appendices	
	Nederlandse samenvatting	283
	Curriculum Vitae	295
	List of publications	297

